Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study
- PMID: 32014940
- DOI: 10.21873/anticanres.14029
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study
Abstract
Background/aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation.
Patients and methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people.
Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment.
Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.
Keywords: Clinical practice; alectinib; anaplastic lymphoma kinase fusion gene mutation; chemotherapy; non-small cell lung cancer.
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.J Cell Mol Med. 2021 Oct;25(19):9476-9481. doi: 10.1111/jcmm.16897. Epub 2021 Sep 19. J Cell Mol Med. 2021. PMID: 34541785 Free PMC article. Review.
-
Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.Clin Lung Cancer. 2019 Jul;20(4):297-304.e1. doi: 10.1016/j.cllc.2019.02.013. Epub 2019 Feb 26. Clin Lung Cancer. 2019. PMID: 31147208
-
Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.Adv Ther. 2020 Jul;37(7):3311-3323. doi: 10.1007/s12325-020-01392-0. Epub 2020 May 29. Adv Ther. 2020. PMID: 32472430
-
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.Future Oncol. 2021 May;17(14):1709-1719. doi: 10.2217/fon-2020-1119. Epub 2021 Feb 11. Future Oncol. 2021. PMID: 33569983
-
Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.Oncol Res Treat. 2019;42(11):599-606. doi: 10.1159/000502755. Epub 2019 Sep 17. Oncol Res Treat. 2019. PMID: 31527380 Free PMC article. Review.
Cited by
-
Octogenarians With Anaplastic Lymphoma Kinase-rearranged Non-small-cell Lung Cancer: A Case Series.Cancer Diagn Progn. 2022 Nov 3;2(6):711-715. doi: 10.21873/cdp.10165. eCollection 2022 Nov-Dec. Cancer Diagn Progn. 2022. PMID: 36340445 Free PMC article.
-
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998. In Vivo. 2020. PMID: 32606173 Free PMC article.
-
Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing.J Clin Pathol. 2022 Mar;75(3):145-153. doi: 10.1136/jclinpath-2021-207490. Epub 2021 Apr 19. J Clin Pathol. 2022. PMID: 33875457 Free PMC article. Review.
-
Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.In Vivo. 2020 Jul-Aug;34(4):2095-2100. doi: 10.21873/invivo.12013. In Vivo. 2020. PMID: 32606188 Free PMC article.
-
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers.Transl Lung Cancer Res. 2024 Jul 30;13(7):1505-1517. doi: 10.21037/tlcr-24-107. Epub 2024 Jul 25. Transl Lung Cancer Res. 2024. PMID: 39118890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous